Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus sintilimab as second-line treatment for squamous non-small cell lung cancer
ChiCTR2000037914Phase 2Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and sintilimab in Pulmonary squamous cell carcinoma, sponsored by Qilu Hospital of Shandong University. Primary endpoint: Progression-free survival. Started Oct 2020; status: recruiting.
02
Drugs
anlotinibsintilimab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2000037914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037914.